Mutual of America Capital Management LLC Sells 1,160 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mutual of America Capital Management LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,825 shares of the medical device company’s stock after selling 1,160 shares during the quarter. Mutual of America Capital Management LLC’s holdings in DexCom were worth $7,466,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. DSM Capital Partners LLC bought a new stake in DexCom in the fourth quarter valued at about $28,000. Valley National Advisers Inc. increased its holdings in shares of DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Riverview Trust Co bought a new stake in shares of DexCom in the first quarter worth about $32,000. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after acquiring an additional 138 shares in the last quarter. Finally, Smithfield Trust Co increased its holdings in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after acquiring an additional 165 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. Canaccord Genuity Group upped their price objective on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research report on Friday, April 26th. Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Finally, UBS Group upped their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $140.33.

Insider Buying and Selling at DexCom

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now directly owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,102 shares of company stock valued at $755,103. 0.30% of the stock is currently owned by corporate insiders.

DexCom Price Performance

DexCom stock traded down $2.72 during mid-day trading on Monday, reaching $110.97. 1,647,775 shares of the company were exchanged, compared to its average volume of 2,913,617. The company has a fifty day simple moving average of $121.03 and a 200-day simple moving average of $125.38. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The firm has a market cap of $44.13 billion, a PE ratio of 71.59, a PEG ratio of 2.78 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. As a group, equities research analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.